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Background. Besides its major role in cell proliferation, DNA repair, and apoptosis, functional p53 protein is involved in the
induction of antitumor cytotoxic-T-cell activity against carcinoma cells. We aimed to investigate p53 and immune cell markers
utility as diagnostic and prognostic markers of differentiated thyroid cancer (DTC).Methods. ACIS-III system was used to evaluate
p53 and immune cell markers including tumor-associated macrophages (TAM); CD68 and tumor-infiltrating lymphocytes (TIL)
subsets such as CD3, CD4, CD8, and CD20 in 206 thyroid carcinomas, 105 benign nodules, and 18 normal tissues. Also, TP53
was sequenced in 78 out of 164 patients with papillary thyroid carcinoma. Results. P53 expression was observed more frequently
in malignant than in benign lesions (𝑃 < 0.0001) and helped discriminate follicular patterned lesions. In addition, p53 was more
frequent in smaller (𝑃 = 0.0015), unique tumors (𝑃 = 0.0286), with thyroiditis (𝑃 = 0.0486) and without metastasis at diagnosis
(𝑃 = 0.0201). TAM was more frequent in P53 negative tumors (𝑃 = 0.002). Infiltration of CD8+ TIL was found in 61.7% of P53
positive and 25.6% of P53 negative DTC (𝑃 < 0.001). Conclusions. We suggest that p53 and CD8+ TIL immune profile analysis
might be useful in DTC.
1. Introduction
The incidence of cancer has grown around the world during
the last yearsmainly due to the large increase in the number of
cases of small lesions detected because the aging population is
obtaining better access to health care and sensitive diagnostic
tools [1]. Although there are lines of evidence that a large
number of these small tumors would never become clinically
important [2], part of these lesions evolve, and despite the
general good prognosis of differentiated thyroid cancer, up
to 10–15% of patients have an aggressive form of the disease,
which will contribute to the 1,850 deaths from thyroid cancer
estimated to occur in 2013 in the USA [3].
Two major problems haunt the physicians who need to
delineate the best management strategy for their patients
with thyroid nodule: the first one is the indeterminate lesion.
In fact, 15–30% of thyroid nodules evaluated by fine-needle
aspiration cytology are not clearly benign or malignant [4].
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Table 1: Immunohistochemical (IHC) expression of p53 protein using automated cellular imaging system ACIS-III quantitative analysis,
according to histopathological diagnosis.
Histopathology Total number ofpatients
IHQ quantitative analysis in the
whole group
Number of
patients positive
for p53
IHQ quantitative analysis for
positive cases
Mean value Median value Mean value Median value
Benign lesions
Normal thyroid
tissue 16 1.76 1.11 0 — —
Nodular goiter 50 4.82 1.71 8 17.25 15.52
Follicular
adenoma 55 8.75 3.68 19 20.47 15.72
Papillary thyroid
carcinoma 164 51.85 53.59 127 52.32 63.69
Malignant lesions
Classic 106 42.16 32.24 83 62.17 70.70
Follicular
variant 54 38.15 39.18 41 54.30 57.92
Tall cell variant 04 03 49.31 55.08
Follicular
carcinoma 42 11.11 2.17 11 36.36 21.64
A second critical issue is the identification of the most
aggressive cases, especially among papillary thyroid cancers
(PTCs), which would benefit from more aggressive therapy
and followup, sparing the vast majority of thyroid tumors of
invasive costly procedures [5].
A series of molecular markers that may improve the
diagnostic and prognostic scoring systems currently used
in these situations has been recently described; however,
unfortunately, most of these systems still lacking accuracy
are costly and/or difficult to implement in a clinical routine
center [6, 7]. Hence, there is an imperative need for further
developments in the approach to thyroid nodule, aiming to
allow greater individualization of patient care.
TP53 gene exerts a major role in the negative control of
cell proliferation and in controlling signaling cascades impor-
tant in DNA repair and apoptosis [8]. Our group and others
have previously reported that the inheritance ofTP53 variants
might be related to the risk of thyroid tumor development [9,
10], and there is data suggesting thatTP53mutationsmay play
an important role in the malignant transformation of thyroid
cells and thyroid tumor progression [11]. Because some
studies have found TP53 mutations in poorly differentiated
and undifferentiated thyroid carcinomas but not in benign
tumors, and only in a few well-differentiated thyroid cancers,
it has been suggested that mutational inactivation of TP53
occurs at a late stage of tumor progression, contributing to
the development of metastatic forms [12]. Interestingly, there
is a low rate of loss of heterozygosity in chromosome 17p of
differentiated thyroid tumors [13]. In addition, the status of
TP53 gene product, either wild-type or mutant p53 nuclear
protein, has also been linked to tumor chemosensitivity,
radiosensitivity, prognosis, and antitumor immune response
in many human cancer types [14–16].
In this study, we aimed to expand our understanding on
TP53 and its product alterations, as well as the associated
clinicopathological features, to further investigate p53 use as
a diagnostic and/or prognostic marker in DTC patients. In
addition, we investigated the putative correlation between
p53 expression and presence of tumor infiltrating lympho-
cytes (TIL) and tumor-associated macrophages (TAM).
2. Subjects and Methods
2.1. Patients. This study was approved by the Research Ethics
Committee of the institutions involved. We investigated
311 patients whose tissue samples were maintained in the
tissue bank of the Cancer Hospital AC Camargo, Sa˜o Paulo,
Brazil, summarized in Table 1. Two hundred six patients
were diagnosed with thyroid carcinoma: 164 with PTC (106
with the classic form (CPTC); 54 with follicular variant
(FVPTC); and 04 with tall cell variant (TCVPTC)), and 42
with follicular thyroid carcinomas (FTC). Malignant thyroid
tissues collected at surgery immediately snap-frozen in liquid
nitrogen and stored at −80∘C for molecular studies were
obtained from 78 of the patients. In addition, we obtained
105 benign thyroid tissues, including 50 nodular goiters (G)
and 55 follicular adenomas (FA). We also obtained 18 normal
thyroid tissues (NT) from the contralateral lobe of patients
who presented a solitary follicular adenoma. Patients’ demo-
graphic, laboratory, image, and clinical information were
obtained from their charts.
All tumors were carefully and independently reviewed
by two experienced pathologists (JV and FAS) for diagnostic
confirmation, and cases presenting conflicting results or areas
of differentiation were excluded. Formalin-fixed, paraffin-
embedded tissues were examined aiming to select the most
representative areas designed to build a tissue microarray
(TMA, Beecher Instruments, Silver Springs, MD, USA) for
immunohistochemical detection of p53 and immune cell
infiltration. We acquired four tumor tissue cores from each
case. Two spots were chosen from representative areas of the
lesion presenting important leukocyte infiltration, whereas
two other spots were chosen from areas free of leukocytes.
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Table 2: Immunohistochemical expression of p53 protein identified as positive, using automated cellular imaging system ACIS-III
quantitative analysis, according to clinicopathological features of aggressiveness and patient outcome.
Clinicopathological features (𝑁) Quantitative analysis of p53 protein 𝑃-value
Mean Median
Gender (119)
Female (101) 61.92 70.70 0.2940
Male (18) 53.96 53.35
Ethnicity (115)
White (111) 77.59 83.42 0.5473
Non-White (4) 78.70 78.70
Age (119)
≤45 years old (65) 60.29 69.78 0.8791
>45 years old (54) 61.22 64.03
Smoking habit (65)
Smoker (24) 73.65 78.89 0.3998
Nonsmoker (39) 78.43 84.84
Tumor size (119)
<2 cm (63) 69.54 77.91
0.00152–4 cm (35) 55.80 56.93
>4 cm (21) 42.40 32.72
Extrathyroidal invasion (117)
Yes (60) 57.26 57.12 0.0969
No (57) 65.73 78.72
Capsulation (102)
Yes (30) 65.53 71.74 0.0762
No (72) 54.47 53.45
Multifocality (119)
Yes (45) 53.27 55.08 0.0286
No (74) 65.24 74.14
Metastasis at diagnosis (119)
Present (43) 51.34 46.01 0.0201
Absent (76) 66.02 75.75
Thyroiditis (119)
Present (39) 69.38 78.72 0.0486
Absent (80) 56.49 57.12
Disease stage (TNM) (124)
I (79) 62.23 70.70
0.6140
II (13) 58.32 74.44
III (15) 51.35 53.59
IV (1) 86.87 —
IVa (11) 55.87 57.31
IVb (4) 43.29 41.02
IVc (1) 56.93 —
Outcome (109)
Free of disease (100) 58.26 60.14 0.9605
Recurrent (9) 57.14 57.31
P53 protein immunohistochemical expression was cor-
related with clinicopathological parameters, such as age,
gender, ethnic group, tumor size,multifocality, extrathyroidal
invasion, presence of lymph node metastases, and out-
come (recurrence/metastasis-free survival), as summarized
in Table 2.
Patients were followed with periodic whole-body scans
and serum TSH and thyroglobulin (Tg) measurements,
according to a standard protocol based on current inter-
national management guidelines that included X-ray, ultra-
sonography, computed tomography scan, and other eventual
procedures to detect distant metastasis for a period of 12–298
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months (53.8 ± 41 months) [17]. Patients presenting or with
suspicion of high nonstimulated serum Tg levels (>2mg/dL)
were submitted to a thorough image search. We defined
tumors as recurrent and/or presenting long distance when
patients showed serum Tg levels > 2mg/dL and/or the above
mentioned image scans were positive for metastasis. Thyroid
cancer patients were classified as free of disease in 142 cases
(85%) andwith recurrence in 25 cases (15%, including 10 dead
from disease). Thirty-nine patients could not be classified
into any of these two groups and were further excluded from
any analysis involving outcome. Aggressiveness at diagnosis
was ascertained using American Joint Committee on Cancer
(AJCC) TNM system for differentiated thyroid carcinoma
[17].
2.2. Immunohistochemical (IHC) Detection of p53 and Infiltra-
tion of Immune Cells. Five micrometer sections of the TMA
were placed on electrically charged slides, deparaffinized
and rehydrated in decreasing concentrations of alcohol. The
endogenous peroxide activity was blocked with H
2
O
2
for
15min. All tissue sections were subjected to heat-induced
antigen retrieval, using 10% citrate buffer (10mM, pH 6.0)
in a steamer (90∘C for 30 minutes). Tissue sections were
then incubated overnight at 6∘C, using monoclonal mouse
anti-human p53 antibody (clone DO-7; monoclonal, DAKO,
Carpinteria, CA, USA) diluted at 1 : 1500.This antibody reacts
with both the wild-type and mutant type of the p53 protein.
Immune cell markers included tumor-associated macro-
phages (CD68) and tumor-infiltrating lymphocyte subsets,
such as CD3, CD4, CD8, and CD20, always evaluated in
intraepithelial infiltrating cells located within cancer cell
nests.
The advanced biotin-free polymer detection system was
used (DAKO, Carpinteria, CA, USA). DAB (3.3-diamino-
benzidine-tetrahydrochloride; Sigma, St. Louis, MA, USA)
was applied as chromogen for five minutes, at room tempera-
ture. Sectionswere counterstainedwith hematoxylin. Positive
and negative controls were run in the same batch of reaction.
2.3. IHC Evaluation. Slides were quantified by at least two of
the authors (MAM, LLC and/or ECM) and then submitted
to other two independent score evaluations performed by
two experienced pathologists (JV and FAS), both blinded
to tumor features. Cells were considered positive for p53
when a clear-cut brown staining was observed in the nucleus,
as demonstrated in Figure 1. Tumor-infiltrating lymphocytes
and tumor-associated macrophages were considered positive
for immunohistochemical markers when a clear-cut brown
staining was observed in the typical corresponding cellular
localization. An individual evaluation of immune cell mark-
ers was completed for each tissue spot, estimating the number
of positive cells per TMA spot, considering an approximate
area of 0.79mm2. The cases were grouped into categories
for statistical analysis: negative (no positive cell) and positive
(presence of positive cells in each spot).
Immunohistochemical expression of p53 was analyzed
using the automated cellular imaging system ACIS-III
(Chroma Vision Medical Systems, Inc., DAKO). Briefly, each
tissue spot was digitalized through the system software, and
a numerical value proportional to the percentage of stained
nuclei was attributed by the computer analysis, as previously
reported by our group [18].
2.4. TP53 Gene Sequencing and Analysis. The frozen tissues
removed from the AC Camargo Hospital Biobank were sub-
jected to histological analysis by pathologists (FAS and JV) to
assess the percentage of malignant tumor tissue. Only sam-
ples with at least 70% of malignant cells were included in the
study. The samples were manually dissected, and areas con-
taining nonneoplastic tissues, fibrosis, fat, or other contami-
nants were removed. Genomic DNA from 78 tumor samples
was extracted from frozen specimens, using a standard pro-
teinase K-phenol-chloroform protocol. Exons 2–11 of TP53
(NM 000546) were directly sequenced. Each exon was indi-
vidually amplified using 50 ng of genomic DNA. The poly-
merase chain reactions (PCRs) contained 0.2𝜇mol/L of each
primer, 0.2mmol/L of each dNTP, 2.0mmol/L MgCl
2
, and
0.5U Platinum Taq DNA Polymerase (Invitrogen, Carlsbad,
CA) in a final reaction volume of 20 𝜇L. The thermal cycling
conditions included an initial cycle of 2min at 94∘C, followed
by 35 cycles of 30 s at 94∘C, 30 s at 57∘C, 45 s at 68∘C at specific
primer annealing temperature of 57 or 59∘C and a final
extension of 10min at 68∘C. PCR products were purified with
ExoSAP-IT (USB Products, Cleveland, OH) and sequenced
in both directions. Sequencing reactions were run using Big
Dye v.3.1 (Applied Biosystems, Carlsbad, CA) and separated
on an ABI Prism 3130xl (Applied Biosystems). All sequences
were analyzed using CLC Bio software (CLC Bio, Cambridge,
MA) and compared with the TP53 sequence. All identified
mutations were compared with TP53 in the International
Agency for Research on Cancer database (http://p53.iarc.fr/).
All pathogenic changes were confirmed in a second PCR
reaction, using PlatinumTaqHigh-Fidelity DNA Polymerase
(Invitrogen) under the same conditions as above.
2.5. Statistical Analysis. Statistical analysis was carried out
using the SAS System for Windows (Statistical Analysis
System, version 9.1.3, Service Pack 3; Institute Inc, 2002-
2003, Cary, NC, USA). Factors that affected recurrence-
free survival were calculated using proportional hazard
regression analysis and Kaplan-Meier survival curves with
log-rank comparison. Nonparametric analysis of genotypes
was performed using either the chi-square or Fisher’s exact
test, as indicated. A multivariate logistic regression model
was applied using quantitative data of p53 immunostaining
as dependent variables and clinicopathological features of
tumor aggressiveness as explicative variables. Cox regression
model was used to find independent prognostic markers.
Mann-Whitney tests were used to compare continuous or
arranged measures between two groups; Kruskal-Wallis test
was used to compare three or more groups. The best cut-
off point to predict malignancy was evaluated using receiver
operating curve (ROC) analysis based on predicted probabili-
ties from logistic regressionmodels.The accuracy, sensitivity,
specificity, and predictive values were also evaluated. All tests
were conducted at the significance level 𝑃 = 0.05.
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Figure 1: Immunohistochemical expression of p53 in thyroid lesions. Scarce cells are positive in one case of adenoma (×500); (b) negative
goiter nuclei (×400); (c.1) papillary carcinoma showing high expression of p53 (×400); (c.2) papillary carcinoma showing negative expression;
(d) follicular variant of papillary thyroid cancer showing moderate expression of the protein (×640); and (e) follicular carcinoma showing
high expression of p53 (×400).
3. Results
As expected, DTC patients were predominantly female
(80.4%) aged 7–88 years old or 45.6±16.3 years at the time of
diagnosis.
3.1. P53 Protein Quantitative Analysis. We defined p53 pos-
itivity when the tumor area presented at least 8.21% of
nuclei stained. This cut-off value was based on a ROC curve,
comparing malignant lesions (visually positive stained) with
benignant lesions (predominantly negative). Among the 206
DTC patients studied, 127 (77.4%) out of 164 PTCs were posi-
tive for p53, and 11 (26.2%) out of 42 FTCwere positive.When
we considered PTC variants, 83 CPTC (79.0%), 41 FVPTC
(75.9%), and 3 TCVPTC (75.0%) were positive for p53. The
benign lesions presented less p53 positivity, given that only
27 (25.7%) out of 105 benign lesions presented some positivity
for p53. FA were the benign lesions more frequently positive
for p53: 19 out of the 55 adenomas (34.5%) presented positive
nuclei. Among the goiters, positivity was even less frequent:
only 8 out of the 50 lesions (16.0%) stained positive. No NT
(0%) was considered positive for p53 staining (Figure 2).
3.2. P53 for Diagnostic Purposes. The IHC quantitative anal-
ysis results, according to histopathological diagnosis, are
summarized in Table 1 and demonstrate different expression
levels among distinct thyroid tissues. P53 expression levels
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Table 3: TP53 genetic alterations in PTC patients, according to histopathological subtypes and the mean p53 protein expression quantified
with the automated cellular imaging system ACIS-III.
Histopathology
of PTC
(total of cases)
TP53 alteration Expression of p53 protein
Number of
cases
Distribution
of alleles Nucleotide Local AA change
Mutation
type dbSNP ID Mean Median
CPTC (54)
43 16 CG/27 GG C11117G Intron 2 — Intronic rs1642785 65.70 77.22
18 14 GC/04 CC G11446C Exon 4 R72P Missense rs1042522 62.48 74.40
02 02 AG A12708G Exon 6 R213R Silent rs1800372 74.88 74.88
04 04 CT C13491T Intron 7 — Intronic rs12947788 88.45 90.89
01 01 AT A17021T Intron 10 — Intronic rs17880847 Unavailable tissue
01 01 TG T16987G E´xon 10 S366A Missense rs17881470 94.80 —
FVPTC (23)
18 07 CG/11 GG C11117G Intron 2 — Intronic rs1642785 71.54 85.04
01 01 CA C11299A Intron 3 — Intronic rs17883323 92.61 —
08 05 GC/03 CC G11446C Exon 4 R72P Missense rs1042522 77.49 94.45
01 01 AG A12708G Exon 6 R213R Silent rs1800372 59.59 —
02 02 CT C13491T Intron 7 — Intronic rs12947788 52.71 52.71
01 01 GA G13925A Intron 8 — Intronic — 95.66 —
TCVPTC (1) 01 01 GG C11117G Intron 2 — Intronic rs1642785 23,28 —
P < 0.0001
0
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Figure 2: Box plot graph with the percentage of stained nuclei
quantified by using ACIS III in all the studied thyroid tissues.
were significantly higher in malignant than in benign lesions
(𝑃 < 0.0001). Using a cutoff of 8.210, a ROC curve
distinguished malignant from benign cases with 71.7% sensi-
tivity; 85.1% specificity; 93.6%positive predictive value; 49.5%
negative predictive value; and 75% accuracy. A comparison
of the different histological groups (NT, G, FA, FTC, CPTC,
FVPTC, TCVPTC) showed that quantitative IHC analysis
could differentiate NT from CPTC (𝑃 < 0.001); NT from
FVPTC (𝑃 < 0.001); G from CPTC (𝑃 < 0.001); G from
FVPTC (𝑃 < 0.001); FA from CPTC (𝑃 < 0.001); FA from
FVPTC (𝑃 < 0.001); CPTC from FTC (<0.001); FVPTC from
FTC (𝑃 < 0.001). Considering that the differential diagnosis
of FVPTC from FTC and FA can be problematic, we investi-
gated the utility of p53 as a diagnostic marker. A ROC curve
identified 13.710 as a cutoff point that distinguished FVPTC
from FA with 68.6% sensitivity; 81.5% specificity; 77.8%
positive predictive value; 73.3% negative predictive value, and
75.23% accuracy. Using 6.740 as a cut-off point, we were
able to differentiate FVPTC from FTCwith 70.7% sensitivity;
78.4% specificity; 72.5% positive predictive value; 78.9% neg-
ative predictive value, and 74.9% accuracy. A box plot graph
presented in Figure 2 demonstrates that although the differ-
ent groups of lesions present considerable superposition of
values, p53 expression levels were able to characterize them.
3.3. P53 as a Prognostic Marker. Since p53 profiles were sig-
nificantly different among PTCs and FTC and protein
expression was considerably higher and more frequent in
PTC patients, who were the most prevalent in our cohort,
we decided to further characterize p53 IHC profile com-
pared with demographic characteristics, clinical pathological
parameters, and outcome of PTC patients positive for p53
staining. These data are summarized in Table 2.
Using tumor size categories (<2 cm, 2–4 cm, >4 cm), we
observed that p53wasmore frequently found staining smaller
tumors (<2 cm) than tumors larger than 4 cm (𝑃 < 0.01).
P53 was more frequent in solitary nodules than in multifocal
tumors (𝑃 = 0.0286) and tended to appearmore frequently in
encapsulated tumors than in those without capsule, although
the statistical comparison showed a marginal 𝑃 value (𝑃 =
0.0762). In addition, p53 immunostaining was more fre-
quent in patients without thyroiditis than in patients with
thyroiditis (𝑃 = 0.0486), as presented in Table 2. Patients
who presented metastasis at the diagnosis had fewer p53
stained nuclei than patients without metastasis (𝑃 = 0.0201).
Unfortunately, the Kaplan-Meier survival curve was not able
to confirm p53 as a factor affecting disease-free survival.
3.4. TP53 Genotypic Alterations. We investigated 78 PTC out
of the 164 cases (54 CPTC, 23 FVPTC, and 01 TCVPTC)
for the presence of genotypic alterations that could be
related to protein expression and clinicopathological features.
Sequencing data are summarized in Table 3. A comparison
between p53 protein profile and the corresponding cases of
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Table 4: Comparison between p53 IHC profile and corresponding TP53 genotype.
Altered cases Wild-type cases
𝑃 value
Mean Median Mean Median
Intron 2 73.35 71.79 83.42 77.99 N.S.
Exon 4 66.68 77.10 76.20 83.42 N.S.
Exon 6 69.78 70.70 73.15 82.83 N.S.
Intron 7 72.70 81.39 76.55 90.72 N.S.
Intron 3 92.61 ∗ 73.59 82.15 ∗
Intron 10 Tissue unavailable for IHC analysis 73.61 82.15 —
Exon 10 94.80 ∗ 73.74 83.43 ∗
Intron 8 95.66 ∗ 77.34 83.43 ∗
∗Analysis was not possible because only one patient had alterations.
genotype did not demonstrate any association, as shown in
Table 4. Genotypes did not correlate neither with clinical nor
with any pathological feature or with patient outcomes.
3.5. P53 Expression and Tumor-Associated Macrophages
and Tumor-Infiltrating Lymphocytes. We further analyzed
whether P53 expression would be associated with the pres-
ence of infiltration of immune cells. We observed that 89.6%
of P53 positive tumors presented TAM,whereas only 71.4% of
P53 negative tumors presented TAM (𝑃 = 0.002). We did not
find any association between P53 expression and infiltration
of CD3+ TIL. A marginal association was found between
P53 expression and infiltration of CD4+ TIL (𝑃 = 0.051).
Interestingly, we observed that 61.7% of P53 positive tumors
presented infiltration of CD8+TIL.However, CD8+TILwere
found in only 25.6% of P53 negative tumors (𝑃 < 0.001).
4. Discussion
Examining both p53 and TP53 gene in a clinical context, we
demonstrated that protein profile may discriminate different
groups of follicular thyroid lesions, confirming recent data
that suggest that p53may have a clinical utility as a diagnostic
marker [19]. In addition, we found p53 expression to be asso-
ciated with several characteristics well recognized as better
prognosis factors such as tumor size, presence of a tumor
capsule, presence of thyroiditis, absence ofmultifocal tumors,
and absence of metastasis at the time of diagnosis [20, 21].
Somatic TP53 gene mutations have been reported in
about half of all cancers and are believed to be critical
determinants of the phenotype of many forms, including
thyroid tumors [22]. TP53 has long been known to be rarely
mutated in well-differentiated thyroid tumors, whereas it is
frequently altered in poorly differentiated or undifferentiated
cancers [19, 23, 24]. However, the paradigm that this tumor
suppressor gene is only involved in advanced cancer progres-
sion is contradicted by a series of evidence indicating that
it also plays an important role in the early stages of gastric
[25], hepatocellular [26], lung [27], and many other tumors,
including thyroid cancer [23]. In fact, increased p53 protein
levels were observed by immunohistochemistry not only in
anaplastic and poorly differentiated thyroid cancer where p53
mutations are frequent but also in well-differentiated cancers,
in the absence of any p53 mutation [28]. Confirming our
data, Balta et al. recently showed that p53 was significantly
augmented in PTC patients when compared with benign
thyroid disorders [23]. These authors also found p53 more
frequently expressed in tumorswithmore aggressive features,
a finding difficult to interpret, since the patients they investi-
gated did not correspond to the usual profile of DTC patients
seen in clinical practice [29]. Conversely, other studies also
found the protein associated with features of aggressiveness
[30, 31], whereas some authors failed to find any relationship
between p53 expression and clinicopathological features [24].
Differences concerning aggressiveness criteria and outcome
characterization, in addition to the use of different p53 anti-
bodies and IHC techniques, may explain these controversial
results [29]. Our data, using a quantitative IHC analysis of
a large number of patients managed according to a same
protocol, and an antibody that recognizes both wild-type and
mutant protein, indicate that p53 exerts an important physio-
logical role in well-differentiated thyroid tumor containment,
especially among papillary thyroid carcinomas.
We observed that tumors positive for p53 expression fre-
quently presented an infiltration of amixture of immune cells,
such as CD8+ TIL and TAM. We previously demonstrated
that the presence of CD8+ TIL and TAM is associated with
nonaggressive phenotype of DTC [32]. The association of
p53 expression and the presence of CD8+ TIL/TAM may
help to explain, at least in part, the association between p53
expression and nonaggressive phenotype of our samples.
It has been proposed that functional p53 protein is
involved in the induction of antitumor CD4+ cytotoxic-T-
cell activity against carcinoma cells [33]. In addition, p53
peptides may be processed and presented to host immune
cells by a variety of mechanisms [34, 35]. In fact, the
aberrant expression of p53 protein in tumor cells versus the
normal expression in nontumor cells provides an immuno-
logical window for the use of p53 as a tumor antigen for
immunotherapy [36].
In addition, we demonstrated a lack of relationship
between p53 protein expression and TP53 mutation status.
Five out of the eight alterations we found are intronic and,
therefore, may not result in protein alterations. Concerning
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the other three exonic alterations, one is a synonymmutation
that probably does affect neither the gene nor the protein
expression, which could explain why the corresponding
levels of p53 protein were not augmented. Another is one
of the most common TP53 polymorphisms; 26 out of 78
cases presented this polymorphism, and heterozygosis was
found in 19 (73.08%) of the 26 cases presenting this exon 4
alteration. These last cases also did not present significant
protein expression variation, suggesting that the presence
of a wild-type allele could compensate the loss of function
of the altered one, likewise described in many diseases in
which carriers of only one mutant allele present a normal
phenotype [37]. And the mutation in exon 10 has not been
previously described in thyroid nodules. Our data do not
support the current idea that p53 expression is directly related
to the presence ofmutations in TP53 gene [8, 38]. Conversely,
they reinforce some recent results obtained in melanomas
in which, despite the high levels of protein expressed, the
frequency ofmutations/polymorphisms inTP53 genewas not
high [39], suggesting that other mechanisms acting on the
protein and/or its signaling pathway, such as p53 cytoplasmic
retention [40] and MDM2 overexpression [41, 42], might be
involved in wild-type p53 inactivation [38].
In conclusion, we suggest that p53 protein profile analysis
by IHCmight be useful in the differential diagnosis of thyroid
lesions andmay help characterize less aggressive cases that do
not need hard-line management.
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